Cancer treatment 2.5 times more effective in tumors with defective "energy factories" Anshika Mishra30 Jan 2024 9:00 AM ISTCancer Research UK-funded scientists have made an unusual discovery that could help to identify patients who are up to two and a half times more...
Nivolumab shows potential clinical activity for high-risk leukoplakia Medha Baranwal24 Jan 2024 1:00 AM ISTUSA: An immune checkpoint therapy trial revealed that Nivolumab showed potential clinical activity for high-risk oral precancerous disease, adding...
Determine efficacy of immunotherapy in PD-L1 negative and low patients: CDSCO Panel Tells Dr Reddy on Nivolumab Dr. Divya Colin20 Jan 2024 5:30 PM ISTNew Delhi: Based on the Phase I/III clinical trial protocol of the anti-cancer drug Nivolumab presented by the drug major Dr Reddy Laboratories, the...
Bristol Myers Squibb to discontinue trial for colorectal cancer treatment Ruchika Sharma17 Dec 2023 2:45 PM ISTPrinceton: Bristol Myers Squibb has announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and...
USFDA accepts for priority review Bristol Myers Squibb application for Opdivo plus Cisplatin-Based Chemotherapy for urothelial carcinoma Ruchika Sharma7 Dec 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
Bristol Myers Squibb Opdivo in combo with cisplatin based chemotherapy gets EMA validation for Urothelial Carcinoma Ruchika Sharma31 Oct 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its type II variation application for...
Perioperative regimen of neoadjuvant Opdivo, chemotherapy improves event free survival in Resectable Non-Small Cell Lung Cancer: Bristol Myers Squibb Ruchika Sharma25 Sept 2023 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced the Phase 3 CheckMate -77T trial has met its primary endpoint of improved event-free survival...
Bristol Myers Squibb gets European Commission nod for Opdivo as adjuvant treatment for patients with completely Resected Stage IIB or IIC Melanoma Ruchika Sharma23 Aug 2023 11:23 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the...
Immunotherapy drug combination helps extend survival in patients with metastatic melanoma Dr. Kamal Kant Kohli22 Aug 2023 9:45 AM ISTUSA: An immunotherapy drug combination was shown to be an effective second-line therapy for metastatic melanoma, an aggressive and deadly type of...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for Opdivo for adjuvant treatment for Melanoma Ruchika Sharma24 July 2023 11:22 AM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb receives EMA panel recommendation for approval of Opdivo with chemotherapy for lung cancer patients Ruchika Sharma29 May 2023 11:30 AM ISTOpdivo is a programmed death-1 immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore...
Immunotherapy after surgery is beneficial for high-risk bladder cancer patients Dr. Kamal Kant Kohli4 April 2023 10:00 AM ISTUSA: Immunotherapy after surgery increases the chance of staying cancer-free in bladder cancer patients compared to those who received a placebo,...
